Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck wins FTC lawsuit

Lundbeck has announced that a US Federal District Court has ruled in its favour in a suit filed in 2008 by the US Federal Trade Commission

Lundbeck has announced that a US Federal District Court has ruled in its favour in a suit filed in 2008 by the US Federal Trade Commission (FTC). The court found that Ovation Pharmaceuticals, a company that has since been acquired by Lundbeck, did not violate antitrust laws when it acquired NeoProfen (ibuprofen lysine), an injection used in premature infants, from Abbott Laboratories.

The drug treats babies with patent ductus arteriosus (PDA), a condition in which the blood vessel connecting two major arteries of the heart fails to close on its own soon after birth.

The lawsuit was filed against Ovation by the FTC and the State of Minnesota in the Federal District Court of Minnesota. The suit objected to the fact that the acquisition meant that the company marketed the only two drugs for the treatment of PDA, Indocin (indomethacin) and NeoProfen, which Ovation bought from Abbott in 2006.

In the 2008 complaint, the FTC claimed that once Ovation had bought up the competition, it raised the price of Indocin nearly 1,300 percent, from $36 to about $500 a vial, and that when the company subsequently launched NeoProfen in July 2006, it set a similarly inflated price.

However, Lundbeck said on Wednesday that the Court found the acquisition did not reduce competition in any market for the treatment of PDA.

9th September 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics